What are endocervical squamous metaplastic cells?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What Are Endocervical Squamous Metaplastic Cells?

Endocervical squamous metaplastic cells are immature squamous cells that arise from the transformation of endocervical columnar epithelium into squamous epithelium, primarily occurring in the cervical transformation zone at the squamocolumnar junction. This process, called squamous metaplasia, represents a normal physiological response but creates the anatomic site where over 90% of cervical cancers develop 1.

Cellular Origin and Development

Squamous metaplastic cells originate from two potential sources in the endocervix:

  • Reserve cells beneath the endocervical columnar epithelium serve as the primary progenitor cells that proliferate and differentiate into squamous epithelium 2, 3
  • Endocervical columnar cells themselves may be bipotential, capable of differentiating into both columnar and squamous cell types 3

The transformation zone represents the region where endocervical columnar epithelium undergoes active squamous metaplasia, creating a dynamic area of cellular change 1.

Clinical Significance in Cervical Cancer Screening

High-Risk Location for Malignancy

The transformation zone containing metaplastic cells is disproportionately susceptible to HPV-induced carcinogenesis:

  • Greater than 90% of cervical cancers develop specifically in the transformation zone, despite this being a small anatomic region 1
  • HPV16-immortalized cells from the transformation zone and endocervix demonstrate significantly more dysplastic differentiation compared to ectocervical cells, with higher Ki-67 proliferation markers and increased invasive potential 1
  • Immature squamous metaplasia and proliferating reserve cells are the specific cellular targets where HPV infection leads to squamous cell carcinoma development 2

Cytologic Detection and Interpretation

When metaplastic cells appear on cervical cytology:

  • Presence of metaplastic squamous cells (MSC) on liquid-based cytology is associated with higher detection rates of high-grade squamous intraepithelial lesions (HSIL), with HSIL/NILM ratios of 0.0044 for MSC alone and 0.0056 when both endocervical and metaplastic cells are present 4
  • Atypical squamous metaplastic (ASM) cells carry substantial clinical concern: 44.2% are associated with HSIL on biopsy, 17.7% with low-grade squamous intraepithelial lesion (LSIL), and only 38.1% are benign 5
  • The presence of MSC indicates adequate sampling of the transformation zone, the critical area for cancer detection 4

Pathophysiology of HPV Infection

Metaplastic cells are particularly vulnerable to HPV-induced transformation:

  • HPV preferentially infects subcolumnar reserve cells and immature squamous metaplasia rather than mature stratified squamous epithelium 2
  • HPV16 and HPV18 account for 65-75% of all cervical cancers, with HPV16 causing approximately 55-60% and HPV18 causing 10-15% 6
  • Persistent HPV infection (especially HPV16 for one to two years) confers a 20-30% risk of developing CIN3+ over five years 6

Management Implications

When Atypical Metaplastic Cells Are Detected

Given the high association with HSIL (44.2% on biopsy), atypical squamous metaplastic cells warrant aggressive evaluation 5:

  • Immediate colposcopy is indicated for any atypical glandular cells (AGC) or atypical metaplastic cells 6
  • HPV DNA testing at the time of colposcopy is preferred for women with atypical endocervical or glandular cells 6
  • Diagnostic excisional procedures providing intact specimens with interpretable margins are recommended when AGC favors neoplasia or adenocarcinoma in situ is suspected 6

Common Pitfalls

  • Poor reproducibility of ASM diagnosis exists among pathologists (only 20% overall agreement), necessitating second opinions and refined diagnostic criteria 5
  • HPV DNA testing alone or repeat cytology alone is unacceptable for initial triage of AGC and atypical metaplastic cells—colposcopy is mandatory 6
  • The presence of benign-appearing metaplastic cells should not provide false reassurance, as the transformation zone remains the highest-risk anatomic site regardless of cytologic appearance 1

References

6
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

In a 23‑year‑old woman with dysuria, burning and tearing sensation during and after intercourse, should she be referred to a gynecologist first or a urologist?
What information should be included on the order for a 24‑hour urine collection?
In a 15‑year‑old male with persistent left lower‑quadrant abdominal tenderness and bruising, right‑sided back pain radiating to the ribs, and new left great‑toe stabbing pain with tingling after a recent appendectomy, what imaging studies and medical management are indicated?
How should a 23-year-old male presenting with dysuria and urethral discharge be evaluated and treated?
What is the most appropriate initial evaluation and management for a 26‑year‑old woman with a 2‑3‑week history of severe right‑breast pain radiating to the shoulder and neck, no palpable mass, skin changes, nipple discharge, or systemic symptoms, and a recent cessation of breastfeeding?
What alternative progestins or formulations can be used instead of micronized oral progesterone?
How long does a 15 µg dose of morphine administered intrathecally (subdural space) last?
In a 28-year-old man with three days of hematochezia and a history of intermittent bleeding, whose colonoscopy three years ago revealed microscopic colitis and hemorrhoids, what investigations should be initiated now and should treatment be started?
When should inhaled corticosteroids be prescribed for COPD patients, considering exacerbation history, eosinophil count, and current bronchodilator therapy?
What is the appropriate dosing regimen for clonidine HCl 0.1 mg tablets to be taken 1–2 tablets three times daily as needed (PRN)?
What are the recommended pharmacologic treatments for managing co‑occurring symptoms in individuals with autism?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question